(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

Aptiv is one of a number of multinationals gathering in Shanghai to test the pulse of China's smart manufacturing market, ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market Merck experts to provide ...

Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Merck's recently approved vaccine, however, gives Pfizer some major competition. The shot, called Capvaxive, protects against bacterial strains that cause about 84% of cases of adult pneumoccocal ...

The shots are also suggested for certain adults and children who are immunocompromised. A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes. Modifi Biosciences, a spin out of Yale University founded in 2021, ...